Skip Therapeutics

Company Overview

Snapshot

Founded in January 2021 by Ariel Feiglin, Skip Therapeutics operates with 1–10 employees. The company has secured funding across one round from three investors, including RMGP Biopharma Investment Fund and FutuRx. In May 2021, the company received seed funding from RMGP Biopharma Investment Fund, FutuRx, and Israel Innovation Authority.

Business overview

Skip Therapeutics is a Health Tech & Life Sciences company focused on developing personalized RNA-based treatments for rare genetic diseases. Utilizing a proprietary computational engine, the company's bioinformatic pipeline analyzes disease-causing mutations to identify optimal molecular strategies for restoring protein function through splice-modulating antisense oligonucleotides (ASOs). This approach enables the identification of treatable patient cohorts and optimizes target selection, with top computational candidates undergoing experimental validation for therapeutic development. Skip Therapeutics operates within the Pharmaceuticals, Biotechnology, and Drug Discovery & Development sectors.

Company Intelligence Q&A

When was Skip Therapeutics founded?

Skip Therapeutics was founded in January 2021.

Who is a co-founder of Skip Therapeutics?

Ariel Feiglin is a co-founder and CSO of Skip Therapeutics.

What is Skip Therapeutics' primary focus?

Skip Therapeutics focuses on developing personalized RNA-based treatments for rare genetic diseases using a novel computational engine.

What is the employee count for Skip Therapeutics?

Skip Therapeutics has 1–10 employees.

What was a key early funding event for Skip Therapeutics?

In May 2021, Skip Therapeutics received seed funding from RMGP Biopharma Investment Fund and FutuRx.